ArticleDiscover oncology2026
Integrated multi-target pharmacology of ginseng in acute myeloid leukemia through single-cell sequencing, molecular docking, network pharmacology, and in vitro experiments.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is a heterogeneous disease of the hematological system. It is characterized by the rapid clonal expansion of abnormally differentiated myeloid progenitor cells within a complex microenvironment. Ginseng has shown anticancer effects in AML. However, the function and mechanism of the major active component of ginseng in AML still remain to be elucidated. This study aims to explore the potential therapeutic targets and molecular mechanisms of ginseng in the treatment of AML.
methodsWe analyzed 10 AML patients treated with the uniform chemotherapy regimen using single-cell RNA sequencing (scRNA-seq). Then, we identified potential targets of ginseng and AML through a combination of network pharmacology and experimental validation using public databases like TCMSP and CTD. After that, we performed protein–protein interaction, gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses to uncover the underlying mechanisms of ginseng in AML. Ultimately, we verified the network pharmacology results via in vitro experiments.
resultsOur results indicated that in non-complete remission (non-CR) AML patients, ginseng comprises 14 anti-AML active compounds and 34 related target genes. KEGG pathway analysis revealed that the AGE-RAGE and NF-κB signaling pathways may play a critical role in modulating chemoresistance in AML treatment. Through network pharmacology and molecular docking, we identified several active compounds in ginseng, including ginsenoside-Rh4, gomisin B, and panaxadiol, which demonstrated strong binding affinities toward core AML targets. In vitro experiments demonstrated that the combination of panaxadiol and Ara-C exhibited synergistic anti-leukemic effects. Further analysis indicated that panaxadiol potentiates the anti-leukemic activity of Ara-C.
conclusionThis study has elucidated the active compounds, potential targets, and signaling pathways of ginseng in overcoming AML chemoresistance. It offers new insights into the molecular mechanisms through which ginseng acts as a potential chemosensitizer of AML and lays a foundation for future research in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.